Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Monday 13 April 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

Digital

Trends outside the headlines, people reviewing graphs

Trends & Insights: February 2026 – A pharmaphorum industry r...

February's Trends Outside the Headlines, trends & insights report showed competitive advantage is increasingly shaped by delivery, not just discovery.

R&D

Scientist using manual and AI methods in lab

From in silico to in vivo: Why development strategy now dete...

As discovery becomes faster and more accessible, the differentiator shifts downstream.

R&D

handshake and corporate body in the background of

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

Market Access

General Counsel in corporate environment

For life sciences, it’s not only about when to bring on a GC...

For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.

Patients

Female patient engages with her female doctor

Return on Engagement (ROE): A new framework to better captur...

Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.

R&D

gut microbiome

Why gut bacteria is the next frontier in medicine

Scientists search far and wide for treatments and cures for the diseases that cause great amounts of human suffering, from cancer to Parkinson's.

Digital

pharmaphorum podcast episode 122a

Avoiding the data swamp: The transformative power of AI

It goes without saying that artificial intelligence (AI), machine learning (ML), generative AI (GenAI), and large language models (LLMs) are already transforming industry, refining and acce

R&D

4 year anniversary of COVID-19 pandemic

4 years on: Remembering the COVID-19 pandemic

This year, Monday 11th March marked four years since the World Health Organization (WHO) declared COVID-19 a global pandemic.

Load more results

Sales & Marketing

Sales & Marketing

Middle East from space, at night

How war in the Middle East is disrupting medical supply chai...

The impact of the geopolitical disruption is starting to tell on global supply chains for medicines and key chemicals for the pharmaceutical industry.

Sales & Marketing

Interview with Craig Ackerman Reuters at Pharma USA 2026

Biotech is back, with Craig Ackerman

In Philadelphia last month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.

Digital

Digital

Trends outside the headlines, people reviewing graphs

Trends & Insights: February 2026 – A pharmaphorum industry r...

February's Trends Outside the Headlines, trends & insights report showed competitive advantage is increasingly shaped by delivery, not just discovery.

Digital

Augmented intelligence concept

Augmented intelligence: The next-gen engine for biopharma in...

Augmented intelligence is strategically valuable because it strengthens both the scientific and financial case for every decision.

Market Access

Market Access

General Counsel in corporate environment

For life sciences, it’s not only about when to bring on a GC...

For founders, the question is no longer just who to hire as GC, but when to hire them, and what comes next.

Market Access

Young girl gives high five to her female doctor, mum also in the consult room

A step forward, but not the finish line: What NICE’s QALY up...

Healthcare in the UK is at an inflection point.

Editor's Picks

Gilead strikes again, penning $5bn deal to buy Tubulis

US judge blocks bid to curb abortion pill access

Kennedy changes vaccine panel charter after legal setback

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

Boehringer transfers schizophrenia DTx selling rights to Click

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Interview at LSX 2026 with Roi Raz

LSX2026: Addressing adult eye cancer, with Roi Raz

Roi Raz, CEO of ReBio Pharma, discusses injectable, bioresorbable sustained release delivery for ophthalmic therapeutics at LSX 2026.

Oncology

Oncologists assessing a brain scan

From preclinical toxicology to clinical safety: The path for...

Successfully navigating the process for drugs with a higher risk-benefit ratio requires a tailored non-clinical programme design.

Oncology

DNA strand

Advancing the case for cell and gene therapies

After the Advanced Therapies Congress, Europe, pharmaphorum spoke with Resolution Therapeutics' Lara Campana and Vianautis' Dr Sam Barker.

Patients

Patients

Female patient engages with her female doctor

Return on Engagement (ROE): A new framework to better captur...

Return on Engagement (ROE) is a call to action to better capture the multifaceted value of patient engagement.

Patients

Brain puzzle with piece missing, letting through the sunlight

Exploring mixed episodes in bipolar I disorder: When mania a...

One of the most misunderstood and often overlooked aspects of BD-I is the occurrence of mixed episodes.

Patients

Interview with Matt Wadyka at Reuters Pharma USA 2026

Making direct-to-patient work, with Matt Wadyka

Matt Wadyka, chief client strategy officer at Inizio Medical, spoke to pharmaphorum about the ins and outs of direct-to-patient programmes in pharma.

R&D

R&D

Scientist using manual and AI methods in lab

From in silico to in vivo: Why development strategy now dete...

As discovery becomes faster and more accessible, the differentiator shifts downstream.

R&D

handshake and corporate body in the background of

Changing Faces: Pharma and biotech, March 2026

A broad mix of senior leadership and scientific and commercial appointments shaped last month’s pharma and biotech hiring activity.

R&D

The Journey of a Small Molecule

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

Editor's Picks

Gilead strikes again, penning $5bn deal to buy Tubulis

US judge blocks bid to curb abortion pill access

Kennedy changes vaccine panel charter after legal setback

Jeito closes 'record' $1.2bn Europe-focused biopharma fund

Boehringer transfers schizophrenia DTx selling rights to Click

News

Sushil Patel

FDA hands another rejection to Replimune's melanoma therapy

Replimune has had its advanced melanoma treatment RP1 turned down by the FDA for a second time, prompting job losses.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company